NEWTOWN SQUARE, Pa., Jan 06, 2006 /PRNewswire via COMTEX/ -- Boiron Laboratories, the world's largest manufacturer of homeopathic medicines, announced today the appointment of Ludovic Rassat to the position of President and Chief Executive Officer of its U.S. division. He will replace Thierry Boiron who held the position since 1995 and has returned to France to serve as managing director of the Boiron Group.
Rassat has worked for Boiron USA since January 2000 serving most recently as vice president of Finance, Administration and Medical Development. He previously worked as a senior auditor at Deloitte in Lyon, France and assistant controller at Diagram in Madrid, Spain and is a graduate of the Institut Commercial Superieur, Paris, France.
"Being part of the leadership that oversaw Boiron's growth in the U.S. has been a tremendous experience," Rassat said. "In the past year we completed the integration of the Dolisos product line and the move of our West Coast Division to a new Simi Valley location. Our future expansion plans include increasing our employees by 20 percent and moving to a larger facility on the East Coast to accommodate our growth."
Boiron, world leader in homeopathy, is a $500 million public company with 3,700 employees in more than 60 countries. Best known for its top-selling flu medicine, Oscillococcinum, Boiron produces over 1,500 homeopathic medicines. For more than 70 years, Boiron has been committed to funding scientific research and educating the public and healthcare professionals on homeopathic medicines. As a pharmaceutical company, Boiron maintains the highest standards in manufacturing, complying with U.S. Food and Drug Administration regulations, the Homeopathic Pharmacopoeia of the U.S., and the Drug Good Manufacturing Practices.